Business Wire

Angion Biomedica Corp. Advances BB3 into Pivotal Phase 3 Clinical Trial in Renal Transplant Patients with Delayed Graft Function

UNIONDALE, N.Y.--(BUSINESS WIRE)--Angion Biomedica Corp. announced today that it plans to commence enrollment of a Phase 3 clinical trial using its investigational drug BB3 to treat delayed graft ...
pharmaphorum

Vifor, Angion organ damage drug fails phase 3 kidney transplant study

Vifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this time in high-risk kidney transplant patients. A phase 3 trial of ANG-3777 revealed ...